The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

Inpatient immune checkpoint inhibitor treatment produces poor outcomes across cancer types, according to the largest study of its kind.

Discover insights from Summit Therapeutics' Q4 2024 earnings call, highlighting the Pfizer collaboration, ivonescimab trial expansions, and strong ...

Rather, TIL have made a decisive move toward an in-licensing strategy, bringing in a bispecific antibody called SYN-2510.

Although PD-L1 testing is standard in some cases, many patients end up on Keytruda without really benefiting,” said Faith Zaslavsky, CEO of Ignite Proteomics and IMAC Holdings. “Our analysis shows ...

Ignite Proteomics announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response to ...

A groundbreaking study shows findings that show a treatment can shrink tumors and improve survival outcomes for patients with ...

Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with ...

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to Cylembio. KEYTRUDA ® is a ...

PFS and OS benefits over chemotherapy were maintained for more than 2 years, and many patients had durable responses to ...